Literature DB >> 16931579

Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Cem Akin1.   

Abstract

Mastocytosis is a disease characterized by pathological mast cell accumulation and activation in tissues. Most patients with mastocytosis exhibit the D816V point mutation in the tyrosine kinase domain of the transmembrane receptor protein Kit, leading to its constitutive activation in bone marrow or lesional skin tissue. Detection of a codon 816 c-kit mutation is included as a minor diagnostic criterion in the World Health Organization's diagnostic criteria for systemic mastocytosis. Determining mutational status of the c-kit gene also has pharmacogenomic implications in patients considered for investigational mast cell cytoreductive therapies. This article reviews diagnostic and therapeutic implications of c-kit mutations as well as other less common molecular abnormalities observed in mast cell disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931579      PMCID: PMC1867614          DOI: 10.2353/jmoldx.2006.060022

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  56 in total

Review 1.  Systemic mastocytosis.

Authors:  Cem Akin; Dean D Metcalfe
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

2.  Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Authors:  E Buchdunger; C L Cioffi; N Law; D Stover; S Ohno-Jones; B J Druker; N B Lydon
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

3.  Presentation of cutaneous mastocytosis in 173 children.

Authors:  R Hannaford; M Rogers
Journal:  Australas J Dermatol       Date:  2001-02       Impact factor: 2.875

Review 4.  Early signaling pathways activated by c-Kit in hematopoietic cells.

Authors:  D Linnekin
Journal:  Int J Biochem Cell Biol       Date:  1999-10       Impact factor: 5.085

Review 5.  Clinical and histopathological aspects of cutaneous mastocytosis.

Authors:  K Wolff; M Komar; P Petzelbauer
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

6.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

Authors:  M C Heinrich; D J Griffith; B J Druker; C L Wait; K A Ott; A J Zigler
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

7.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.

Authors:  Cem Akin; Gerard Fumo; Akif S Yavuz; Peter E Lipsky; Len Neckers; Dean D Metcalfe
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

8.  Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.

Authors:  Amy D Klion; Jamie Robyn; Cem Akin; Pierre Noel; Margaret Brown; Melissa Law; Dean D Metcalfe; Cynthia Dunbar; Thomas B Nutman
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  Cutaneous mastocytosis in children: a clinical analysis of 71 cases.

Authors:  A E Kiszewski; C Durán-Mckinster; L Orozco-Covarrubias; P Gutiérrez-Castrellón; R Ruiz-Maldonado
Journal:  J Eur Acad Dermatol Venereol       Date:  2004-05       Impact factor: 6.166

10.  Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA).

Authors:  Luis Escribano; Beatriz Diaz-Agustin; Antonio López; Rosa Núñez López; Andrés García-Montero; Julia Almeida; Aranzazu Prados; Miguel Angulo; Sonia Herrero; Alberto Orfao
Journal:  Cytometry B Clin Cytom       Date:  2004-03       Impact factor: 3.058

View more
  19 in total

1.  Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis.

Authors:  Cem Akin; Linda M Scott; Can N Kocabas; Nataliya Kushnir-Sukhov; Erica Brittain; Pierre Noel; Dean D Metcalfe
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

Review 2.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 3.  Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors:  C C Yin; L J Medeiros; C E Bueso-Ramos
Journal:  Int J Lab Hematol       Date:  2010-07-07       Impact factor: 2.877

4.  Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis.

Authors:  Alfonso Quintás-Cardama; Matjaz Sever; Jorge Cortes; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-01-23

5.  The need for United States-based guidelines for myeloproliferative neoplasms.

Authors:  Brady L Stein; Susan O'Brien; Peter Greenberg; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

Review 6.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

7.  Recent advances in mast cell clonality and anaphylaxis.

Authors:  Cem Akin
Journal:  F1000 Med Rep       Date:  2009-12-15

8.  Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.

Authors:  Sa A Wang; Lloyd Hutchinson; Guilin Tang; Su S Chen; Patricia M Miron; Yang O Huh; Dan M Jones; Carlos Bueso-Ramos; Srdan Verstovsek; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Am J Hematol       Date:  2013-03       Impact factor: 10.047

9.  Mastocytosis: a disease of the hematopoietic stem cell.

Authors:  Hans-Peter Horny; Karl Sotlar; Peter Valent; Karin Hartmann
Journal:  Dtsch Arztebl Int       Date:  2008-10-03       Impact factor: 5.594

Review 10.  Immunology and clinical manifestations of non-clonal mast cell activation syndrome.

Authors:  Juan-Carlos Cardet; Mariana C Castells; Matthew J Hamilton
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.